CymaBay Therapeutics Inc. (Nasdaq: CBAY) to Ring The Nasdaq Stock Market Closing Bell
May 15 2015 - 10:13AM
What:
CymaBay Therapeutics Inc. (Nasdaq:CBAY), a clinical-stage
biopharmaceutical company developing therapies to treat metabolic
diseases with high unmet medical need, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, Harold Van Wart, Chief
Executive Officer will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Monday, May 18, 2015 – 3:45 p.m. to 4:00 p.m.
ET
CymaBay Therapeutics Inc. Media Contact:
Sujal Shah(510) 293-8800sshah@cymabay.com
Nasdaq MarketSite:
Christine Barna(646) 441-5310Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About CymaBay Therapeutics
Inc. (Nasdaq:CBAY):
CymaBay Therapeutics, Inc. (Nasdaq:CBAY) is a clinical-stage
biopharmaceutical company developing therapies to treat metabolic
diseases with high unmet medical need, including serious rare and
orphan disorders. Arhalofenate, the company's lead product
candidate, has shown two therapeutic actions in a single drug in
multiple Phase 2 gout studies. In gout patients, arhalofenate is
intended to prevent painful flares in joints while at the same time
promoting excretion of uric acid by the kidney, thereby addressing
both the signs and symptoms of gout and the hyperuricemia that is
the root cause of the disease. CymaBay's second product candidate,
MBX-8025 is a potent, selective, orally active PPARδ agonist. A
Phase 2 study of MBX-8025 in patients with mixed dyslipidemia
established that it has an anti-atherogenic lipid profile. CymaBay
has initiated a Phase 2 pilot study of MBX-8025 in patients with
homozygous familial hypercholesterolemia.
For additional information about CymaBay visit
www.cymabay.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of approximately $9.5 trillion and more than
10,000 corporate clients. To learn more, visit: nasdaq.com/ambition
or business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024